Ebdrup Søren, Pettersson Ingrid, Rasmussen Hanne B, Deussen Heinz-Josef, Frost Jensen Anette, Mortensen Steen B, Fleckner Jan, Pridal Lone, Nygaard Lars, Sauerberg Per
Novo Nordisk A/S, Novo Nordisk Park, 2760 Måløv, Denmark.
J Med Chem. 2003 Apr 10;46(8):1306-17. doi: 10.1021/jm021027r.
A new and improved synthesis of the peroxisome proliferator-activated receptor (PPAR) agonist ragaglitazar applicable for large-scale preparation has been developed. The convergent synthetic procedure was based on a novel enzymatic kinetic resolution step. The conformation of ragaglitazar bound to the hPPARgamma receptor was quite different compared to the single-crystal structures of the l-arginine salt of ragaglitazar. In particular, the phenoxazine ring system had varying orientations. Ragaglitazar had high affinity for the hPPARalpha and -gamma receptors with IC(50) values of 0.98 and 0.092 microM, respectively. The lack of hPPARdelta activity could be explained by the absence of binding in the tail-up pocket in the hPPARdelta receptor, in contrast to the hPPARdelta agonist GW2433, which was able to bind in both the tail-up and tail-down pockets of the receptor.